Navigation Links
Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
Date:11/24/2013

SAN DIEGO, Nov. 24, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce results of the Light Study interim analysis on Monday, November 25, 2013 prior to market open. Following the announcement, Orexigen management will host a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).

The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36202424. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application had been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com

McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
2. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
3. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
4. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
5. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
6. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
7. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
8. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
9. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
10. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
11. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... COUNTY, Calif. , May 19, 2016 /PRNewswire/ ... two thirds of the world lacks basic diagnostic ... procedures in the United States ... privileged to such technology. In fact, the WHO ... at risk of avoidable or treatable death, simply ...
(Date:5/19/2016)... -- According to a new market research report "Sunitinib ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected ... 13.9% from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... spread through 26 Pages and in-depth TOC on "Sunitinib ...
(Date:5/19/2016)... , The data will be presented in ... The conclusions of the study point to a ... 90% of the m presenting duration ... of the patients had clinical benefit.     ... study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Clarion ... and safety labels , has been featured in the National Electrical Manufacturers ... eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization news. The publication ...
(Date:5/24/2016)... ... , ... Since 1946, the doctors and staff at Clifton Dental Associates have ... arrives at the office, the staff will make them feel welcome and comfortable. Drs. ... a complete dental treatment plan that is unique to each smile. , Dr. Kayne ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in ... tick bites and how to avoid being bitten this spring. , The official ... , Ticks, small spider-like insects, are known for attaching themselves to their prey while ...
(Date:5/24/2016)... ... May 24, 2016 , ... Today ... module. The cutting-edge feature provides end users with an embedded, real time ... intelligence solution and its analytics engine. , This powerful addition to ...
(Date:5/24/2016)... TN (PRWEB) , ... May 24, 2016 , ... ... vitamin alkaline water, a revolutionary new beverage for pregnant women to prevent morning ... prenatal vitamins and alkaline minerals with the look and taste of water. , ...
Breaking Medicine News(10 mins):